Citations (89)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (27)
Maria Gabriella Matera, Barbara Rinaldi, Luigino Calzetta, Paola Rogliani & Mario Cazzola. (2023) Advances in adrenergic receptors for the treatment of chronic obstructive pulmonary disease: 2023 update. Expert Opinion on Pharmacotherapy 0:0, pages 1-10.
Read now
Read now
Robert M Burkes & Ralph J Panos. (2020) Ultra Long-Acting β-Agonists in Chronic Obstructive Pulmonary Disease. Journal of Experimental Pharmacology 12, pages 589-602.
Read now
Read now
Maria Gabriella Matera, Josuel Ora & Mario Cazzola. (2015) Differential pharmacology and clinical utility of long-acting bronchodilators in COPD – focus on olodaterol. Therapeutics and Clinical Risk Management 11, pages 1805-1811.
Read now
Read now
Masakazu Ichinose, Ayako Takizawa, Toshiyasu Izumoto, Yusuke Tadayasu, Alan L Hamilton, Christina Kunz & Yoshinosuke Fukuchi. (2015) Efficacy and safety of the long-acting β2-agonist olodaterol over 4 weeks in Japanese patients with chronic obstructive pulmonary disease. International Journal of Chronic Obstructive Pulmonary Disease 10, pages 1673-1683.
Read now
Read now
Maria Gabriella Matera, Paola Rogliani & Mario Cazzola. (2015) Indacaterol for the treatment of chronic obstructive pulmonary disease. Expert Opinion on Pharmacotherapy 16:1, pages 107-115.
Read now
Read now
Andrea Rossi & Guido Polese. (2013) Indacaterol: a comprehensive review. International Journal of Chronic Obstructive Pulmonary Disease 8, pages 353-363.
Read now
Read now
Paul Colthorpe, Thomas Voshaar, Thomas Kieckbusch, Erika Cuoghi & Juergen Jauernig. (2013) Delivery characteristics of a low-resistance dry-powder inhaler used to deliver the long-acting muscarinic antagonist glycopyrronium. Journal of Drug Assessment 2:1, pages 11-16.
Read now
Read now
Santiago Quirce, Irina Bobolea & Pilar Barranco. (2012) Emerging drugs for asthma. Expert Opinion on Emerging Drugs 17:2, pages 219-237.
Read now
Read now
Marcos Ribeiro & Kenneth R Chapman. (2012) Comparative efficacy of indacaterol in chronic obstructive pulmonary disease. International Journal of Chronic Obstructive Pulmonary Disease 7, pages 145-152.
Read now
Read now
Kai-Michael Beeh, Frank Wagner, Sanjeev Khindri & Anton Franz Drollmann. (2011) Effect of Indacaterol on Dynamic Lung Hyperinflation and Breathlessness in Hyperinflated Patients with COPD. COPD: Journal of Chronic Obstructive Pulmonary Disease 8:5, pages 340-345.
Read now
Read now
Rania O Salama, Paul M Young, Philippe Rogueda, Arthur Lallement, Ilian Iliev & Daniela Traini. (2011) Advances in drug delivery: is triple therapy the future for the treatment of chronic obstructive pulmonary disease?. Expert Opinion on Pharmacotherapy 12:12, pages 1913-1932.
Read now
Read now
Kenneth R Chapman, Charles M Fogarty, Clare Peckitt, Cheryl Lassen, Dalal Jadayel, Juergen Dederichs, Mukul Dalvi & Benjamin Kramer. (2011) Delivery characteristics and patients’ handling of two single-dose dry-powder inhalers used in COPD. International Journal of Chronic Obstructive Pulmonary Disease 6, pages 353-363.
Read now
Read now
Richard Pavkov, Stefan Mueller, Katrin Fiebich, Dilraj Singh, Frank Stowasser, Giovanni Pignatelli, Benoît Walter, Dominik Ziegler, Mukul Dalvi, Juergen Dederichs & Ilse Rietveld. (2010) Characteristics of a capsule based dry powder inhaler for the delivery of indacaterol. Current Medical Research and Opinion 26:11, pages 2527-2533.
Read now
Read now
Beatrix Balint, Henrik Watz, Carolynn Amos, Roger Owen, Mark Higgins & Benjamin Kramer. (2010) Onset of action of indacaterol in patients with COPD: Comparison with salbutamol and salmeterol-fluticasone. International Journal of Chronic Obstructive Pulmonary Disease 5, pages 311-318.
Read now
Read now
Mario Cazzola, Nicola A Hanania & Maria G Matera. (2010) Arformoterol tartrate in the treatment of COPD. Expert Review of Respiratory Medicine 4:2, pages 155-162.
Read now
Read now
Satomi Onoue, Shingen Misaka, Yohei Kawabata & Shizuo Yamada. (2009) New treatments for chronic obstructive pulmonary disease and viable formulation/device options for inhalation therapy. Expert Opinion on Drug Delivery 6:8, pages 793-811.
Read now
Read now
Carola Seifart & Claus Vogelmeier. (2009) Emerging drugs in chronic obstructive pulmonary disease. Expert Opinion on Emerging Drugs 14:1, pages 181-194.
Read now
Read now
Maria Gabriella Matera, Giacomo Curradi & Mario Cazzola. (2008) Long-acting β2 agonists in asthma and allergic rhinitis. Expert Opinion on Pharmacotherapy 9:9, pages 1531-1539.
Read now
Read now
Tammy SY Mui, SF Paul Man & Don D Sin. (2008) Developments in drugs for the treatment of chronic obstructive pulmonary disease. Expert Review of Clinical Immunology 4:3, pages 365-377.
Read now
Read now
Peter J. Barnes. (2008) Future therapies for chronic obstructive pulmonary disease. Journal of Organ Dysfunction 4:2, pages 66-70.
Read now
Read now
Bruce K Rubin & James B Fink. (2007) Novel medications for asthma: a look at the future. Expert Opinion on Investigational Drugs 16:6, pages 889-897.
Read now
Read now
Bradley E Chipps & Julia M Harder. (2007) Targeted interventions for difficult-to-treat asthma. Expert Opinion on Therapeutic Targets 11:1, pages 11-20.
Read now
Read now
Graeme P Currie. (2006) Effects of asthma treatment: the present and future. Expert Review of Clinical Immunology 2:4, pages 547-560.
Read now
Read now
Samir Malhotra, S F Paul Man & Don D Sin. (2006) Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opinion on Emerging Drugs 11:2, pages 275-291.
Read now
Read now
A Guerra, N E Campillo & J A Páez. (2006) Glycopyrrolate combinations for the treatment of respiratory diseases. Expert Opinion on Therapeutic Patents 16:5, pages 723-728.
Read now
Read now
Girolamo Pelaia, Alessandro Vatrella, Luca Gallelli, Teresa Renda, Mario Caputi, Rosario Maselli & Serafino A Marsico. (2006) Biological targets for therapeutic interventions in COPD: clinical potential. International Journal of Chronic Obstructive Pulmonary Disease 1:3, pages 321-334.
Read now
Read now
Peter Norman. (2006) Long-acting β2 agonists. Expert Opinion on Therapeutic Patents 16:1, pages 99-104.
Read now
Read now
Articles from other publishers (62)
Luca Chiesa, Emilie Sick & Esther Kellenberger. (2023) Predicting the duration of action of β2‐adrenergic receptor agonists: Ligand and structure‐based approaches. Molecular Informatics.
Crossref
Crossref
Aprilian Ria Adisti & Sri Marwiyati. (2023) Developing Children's Language Skills through Storybooks Based on Religious Moderation. Jurnal Obsesi : Jurnal Pendidikan Anak Usia Dini 7:4, pages 4349-4359.
Crossref
Crossref
Jitender Singh, Roshan I. Patel & Anuj Sharma. (2022)
Visible‐Light‐Mediated C‐2 Functionalization and Deoxygenative Strategies in Heterocyclic
N
‐Oxides
. Advanced Synthesis & Catalysis 364:14, pages 2289-2306.
Crossref
Crossref
C.H. McAteer, R. Murugan & J.H. Yamamoto. 2022. Comprehensive Heterocyclic Chemistry IV. Comprehensive Heterocyclic Chemistry IV
217
242
.
Christopher T. Szlenk, Jeevan B. GC & Senthil Natesan. (2021)
Membrane-Facilitated Receptor Access and Binding Mechanisms of Long-Acting
β
2-Adrenergic Receptor Agonists
. Molecular Pharmacology 100:4, pages 406-427.
Crossref
Crossref
Basavarajaiah Suliphuldevara Matada, Raviraj Pattanashettar & Nagesh Gunavanthrao Yernale. (2021) A comprehensive review on the biological interest of quinoline and its derivatives. Bioorganic & Medicinal Chemistry 32, pages 115973.
Crossref
Crossref
Čižmáriková Ružena, Valentová Jindra & Horáková Renáta. (2020) Chirality of β2-agonists. An overview of pharmacological activity, stereoselective analysis, and synthesis. Open Chemistry 18:1, pages 628-647.
Crossref
Crossref
Christopher T. Szlenk, Jeevan B. GC & Senthil Natesan. (2019) Does the Lipid Bilayer Orchestrate Access and Binding of Ligands to Transmembrane Orthosteric/Allosteric Sites of G Protein-Coupled Receptors?. Molecular Pharmacology 96:5, pages 527-541.
Crossref
Crossref
Mario Cazzola, Paola Rogliani & Maria Gabriella Matera. (2019) Ultra-LABAs for the treatment of asthma. Respiratory Medicine 156, pages 47-52.
Crossref
Crossref
Ehtesham Arif & Deepak Nihalani. (2019) Beta2‐adrenergic receptor in kidney biology: A current prospective. Nephrology 24:5, pages 497-503.
Crossref
Crossref
Tufan Güray, Muzaffer Tunçel & Ulku Dilek Uysal. (2018) A validated capillary electrophoretic method for the determination of indacaterol and its application to a pharmaceutical preparation. Journal of Food and Drug Analysis 26:2, pages 842-848.
Crossref
Crossref
Mohamad Abadelah, Henry Chrystyn, Golshan Bagherisadeghi, Gaballa Abdalla & Hassan Larhrib. (2017) Study of the Emitted Dose After Two Separate Inhalations at Different Inhalation Flow Rates and Volumes and an Assessment of Aerodynamic Characteristics of Indacaterol Onbrez Breezhaler® 150 and 300 μg. AAPS PharmSciTech 19:1, pages 251-261.
Crossref
Crossref
Wei Zhang & Jason Yuan. 2016. Applying Pharmacogenomics in Therapeutics. Applying Pharmacogenomics in Therapeutics
221
242
.
Jolyon Mitchell. 2016. Developing Drug Products in an Aging Society. Developing Drug Products in an Aging Society
331
382
.
Li-Jun Guan, Jun Ohtsuka, Masahiko Okai, Takuya Miyakawa, Tomoko Mase, Yuehua Zhi, Feng Hou, Noriyuki Ito, Akira Iwasaki, Yoshihiko Yasohara & Masaru Tanokura. (2015) A new target region for changing the substrate specificity of amine transaminases. Scientific Reports 5:1.
Crossref
Crossref
Ji Jiang, Lilly Li, Hequn Yin, Ralph Woessner, Corinne Emotte, Ruobing Li, Sanjeev Khindri & Hu Pei. (2014) Single- and multiple-dose pharmacokinetics of inhaled indacaterol in healthy Chinese volunteers. European Journal of Drug Metabolism and Pharmacokinetics 40:2, pages 203-208.
Crossref
Crossref
Guy F. Joos, Joseph-Leon Aumann, Carl Coeck, Lawrence Korducki, Alan L. Hamilton, Christina Kunz & René Aalbers. (2015) A randomised, double-blind, four-way, crossover trial comparing the 24-h FEV1 profile for once-daily versus twice-daily treatment with olodaterol, a novel long-acting β2-agonist, in patients with chronic obstructive pulmonary disease. Respiratory Medicine 109:5, pages 606-615.
Crossref
Crossref
Jadwiga A. Wedzicha, Roland Buhl, David Lawrence & David Young. (2015) Monotherapy with indacaterol once daily reduces the rate of exacerbations in patients with moderate-to-severe COPD: Post-hoc pooled analysis of 6 months data from three large phase III trials. Respiratory Medicine 109:1, pages 105-111.
Crossref
Crossref
Peter B. Noble, Chris D. Pascoe, Bo Lan, Satoru Ito, Loes E.M. Kistemaker, Amanda L. Tatler, Tonio Pera, Bindi S. Brook, Reinoud Gosens & Adrian R. West. (2014) Airway smooth muscle in asthma: Linking contraction and mechanotransduction to disease pathogenesis and remodelling. Pulmonary Pharmacology & Therapeutics 29:2, pages 96-107.
Crossref
Crossref
Wanzhen Yao, Changzheng Wang, Nanshan Zhong, Xiaowen Han, Changgui Wu, Xixin Yan, Ping Chen, Wei Yang, Michelle Henley & Benjamin Kramer. (2014) Effect of once-daily indacaterol in a predominantly Chinese population with chronic obstructive pulmonary disease: A 26-week Asia-Pacific study. Respirology 19:2, pages 231-238.
Crossref
Crossref
James F. Donohue, Matthew C. Miles & Jill A. Ohar. 2014. Indacaterol. Indacaterol
1
23
.
R. M. Mroz, L. Minarowski & E. Chyczewska. 2013. Respiratory Regulation - The Molecular Approach. Respiratory Regulation - The Molecular Approach
23
28
.
Yasuo To, Masaharu Kinoshita, Sang Haak Lee, Liang-Wen Hang, Masakazu Ichinose, Yoshinosuke Fukuchi, Tetsuji Kitawaki, Naoko Okino, Niyati Prasad, David Lawrence & Benjamin Kramer. (2012) Assessing efficacy of indacaterol in moderate and severe COPD patients: A 12-week study in an Asian population. Respiratory Medicine 106:12, pages 1715-1721.
Crossref
Crossref
Mirjam Gnadt, Beatrice Trammer, Boris Kardziev, Martin K. Bayliss, Chris D. Edwards, Michael Schmidt & Petra Högger. (2012) Comparison of the bronchodilating effects of inhaled β2-agonists after methacholine challenge in a human lung reperfusion model. European Journal of Pharmaceutics and Biopharmaceutics 81:3, pages 617-626.
Crossref
Crossref
Mario Cazzola, Clive P. Page, Luigino Calzetta & M. Gabriella Matera. (2012) Pharmacology and Therapeutics of Bronchodilators. Pharmacological Reviews 64:3, pages 450-504.
Crossref
Crossref
Corinne Emotte, Olivier Heudi, Fanny Deglave, Adrien Bonvie, Laurence Masson, Franck Picard, Animesh Chaturvedi, Tapan Majumdar, Ashish Agarwal, Ralph Woessner & Olivier Kretz. (2012) Validation of an on-line solid-phase extraction method coupled to liquid chromatography?tandem mass spectrometry detection for the determination of Indacaterol in human serum. Journal of Chromatography B 895-896, pages 1-9.
Crossref
Crossref
Mario Cazzola & Maria Gabriella Matera. 2012. Advances in Combination Therapy for Asthma and COPD. Advances in Combination Therapy for Asthma and COPD
81
101
.
MASAHARU KINOSHITA, SANG HAAK LEE, LIANG-WEN HANG, MASAKAZU ICHINOSE, MOTOI HOSOE, NAOKO OKINO, NIYATI PRASAD, BENJAMIN KRAMER & YOSHINOSUKE FUKUCHI. (2012) Efficacy and safety of indacaterol 150 and 300 µg in chronic obstructive pulmonary disease patients from six Asian areas including Japan: A 12-week, placebo-controlled study. Respirology 17:2, pages 379-389.
Crossref
Crossref
Mirjam Gnadt, Beatrice Trammer, Matthias Freiwald, Boris Kardziev, Martin K. Bayliss, Chris D. Edwards, Michael Schmidt, Godehard Friedel & Petra H?gger. (2012) Methacholine delays pulmonary absorption of inhaled ?2-agonists due to competition for organic cation/carnitine transporters. Pulmonary Pharmacology & Therapeutics 25:1, pages 124-134.
Crossref
Crossref
Peter J BarnesMario CazzolaMaria Gabriella Matera. 2012. Addressing Unmet Medical Needs in COPD Management. Addressing Unmet Medical Needs in COPD Management
64
75
.
Sanjeev Khindri, Ronald Sabo, Stuart Harris, Ralph Woessner, Simon Jennings & Anton F Drollmann. (2011) Cardiac safety of indacaterol in healthy subjects: a randomized, multidose, placebo- and positive-controlled, parallel-group thorough QT study. BMC Pulmonary Medicine 11:1.
Crossref
Crossref
Didier Renard, Michael Looby, Benjamin Kramer, David Lawrence, David Morris & Donald R Stanski. (2011) Characterization of the bronchodilatory dose response to indacaterol in patients with chronic obstructive pulmonary disease using model-based approaches. Respiratory Research 12:1.
Crossref
Crossref
Kenneth R. Chapman, Stephen I. Rennard, Angeli Dogra, Roger Owen, Cheryl Lassen & Benjamin Kramer. (2011) Long-term Safety and Efficacy of Indacaterol, a Long-Acting β2-Agonist, in Subjects With COPD. Chest 140:1, pages 68-75.
Crossref
Crossref
Denis E. O’Donnell, Richard Casaburi, Walter Vincken, Luis Puente-Maestu, James Swales, David Lawrence & Benjamin Kramer. (2011) Effect of indacaterol on exercise endurance and lung hyperinflation in COPD. Respiratory Medicine 105:7, pages 1030-1036.
Crossref
Crossref
Paul W. Jones, Donald A. Mahler, Rupert Gale, Roger Owen & Benjamin Kramer. (2011) Profiling the effects of indacaterol on dyspnoea and health status in patients with COPD. Respiratory Medicine 105:6, pages 892-899.
Crossref
Crossref
Mario Cazzola, Luigino Calzetta & Maria Gabriella Matera. (2011) β2-adrenoceptor agonists: current and future direction. British Journal of Pharmacology 163:1, pages 4-17.
Crossref
Crossref
Stephanie Korn, Edward Kerwin, Sibel Atis, Carolynn Amos, Roger Owen & Cheryl Lassen. (2011) Indacaterol once-daily provides superior efficacy to salmeterol twice-daily in COPD: A 12-week study. Respiratory Medicine 105:5, pages 719-726.
Crossref
Crossref
Motoi Hosoe, Ralph Woessner, Soichiro Matsushima, David Lawrence & Benjamin Kramer. (2011) Efficacy, Safety and Pharmacokinetics of Indacaterol in Caucasian and Japanese Patients with Chronic Obstructive Pulmonary Disease. Clinical Drug Investigation 31:4, pages 247-255.
Crossref
Crossref
Teet Pullerits, Pietro Ventresca & Jan Lötvall. (2011) The duration of bronchodilation of salmeterol and salbutamol as measured by specific airway conductance in healthy subjects. Pulmonary Pharmacology & Therapeutics 24:1, pages 55-58.
Crossref
Crossref
Craig LaForce, Joseph Aumann, Luis de Teresa Parreño, Amir Iqbal, David Young, Roger Owen, Mark Higgins & Benjamin Kramer. (2011) Sustained 24-hour efficacy of once daily indacaterol (300 μg) in patients with chronic obstructive pulmonary disease: A randomized, crossover study. Pulmonary Pharmacology & Therapeutics 24:1, pages 162-168.
Crossref
Crossref
Nicola A. Hanania & Mario Cazzola. 2011. COPD. COPD
99
114
.
Donald P Tashkin & Leonardo M Fabbri. (2010) Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents. Respiratory Research 11:1.
Crossref
Crossref
Claus Vogelmeier, David Ramos-Barbon, Damon Jack, Simon Piggott, Roger Owen, Mark Higgins & Benjamin Kramer. (2010) Indacaterol provides 24-hour bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropium. Respiratory Research 11:1.
Crossref
Crossref
Mario Cazzola, Andrea Segreti & Maria G Matera. (2010) Novel bronchodilators in asthma. Current Opinion in Pulmonary Medicine 16:1, pages 6-12.
Crossref
Crossref
Anne-Marie Scola, Matthew Loxham, Steven J Charlton & Peter T Peachell. (2009) The long-acting β-adrenoceptor agonist, indacaterol, inhibits IgE-dependent responses of human lung mast cells. British Journal of Pharmacology 158:1, pages 267-276.
Crossref
Crossref
Thierry Bouyssou, Klaus Rudolf, Christoph Hoenke, Philipp Lustenberger, Andreas Schnapp & Ingo Konetzki. (2009) Studies towards topical selective ?2-adrenoceptor agonists with a long duration of action. Bioorganic & Medicinal Chemistry Letters 19:17, pages 5237-5240.
Crossref
Crossref
Christine A. Sorkness. 2009. Middleton's Allergy: Principles and Practice. Middleton's Allergy: Principles and Practice
1485
1503
.
Louis-Philippe Boulet. 2009. Middleton's Allergy: Principles and Practice. Middleton's Allergy: Principles and Practice
1345
1365
.
Susan Summerhill, Timothy Stroud, Roshini Nagendra, Christelle Perros-Huguet & Michael Trevethick. (2008) A cell-based assay to assess the persistence of action of agonists acting at recombinant human β2 adrenoceptors. Journal of Pharmacological and Toxicological Methods 58:3, pages 189-197.
Crossref
Crossref
M Cazzola & M G Matera. (2008) Novel long-acting bronchodilators for COPD and asthma. British Journal of Pharmacology 155:3, pages 291-299.
Crossref
Crossref
Nicola A. Hanania & Mario Cazzola. 2008. Clinical Asthma. Clinical Asthma
241
250
.
Mario CazzolaMaria Gabriella Matera. (2016) Review: Safety of long-acting β2 -agonists in the treatment of asthma. Therapeutic Advances in Respiratory Disease 1:1, pages 35-46.
Crossref
Crossref
Richard A. Bond, Domenico Spina, Sergio Parra & Clive P. Page. (2007) Getting to the heart of asthma: Can “β blockers” be useful to treat asthma?. Pharmacology & Therapeutics 115:3, pages 360-374.
Crossref
Crossref
Nicola A. Hanania & Amir Sharafkhaneh. (2007) Update on the Pharmacologic Therapy for Chronic Obstructive Pulmonary Disease. Clinics in Chest Medicine 28:3, pages 589-607.
Crossref
Crossref
Zuzana Diamant, J. Diderik Boot & J. Christian Virchow. (2007) Summing up 100 years of asthma. Respiratory Medicine 101:3, pages 378-388.
Crossref
Crossref
Maria Gabriella Matera & Mario Cazzola. (2007) Ultra-Long-Acting ??2-Adrenoceptor Agonists. Drugs 67:4, pages 503-515.
Crossref
Crossref
J. Christian Virchow. 2007. Volkskrankheit Asthma/COPD. Volkskrankheit Asthma/COPD
435
444
.
Peter J. Barnes. (2006) New therapies for asthma. Trends in Molecular Medicine 12:11, pages 515-520.
Crossref
Crossref
. (2006) Current World Literature. Current Opinion in Allergy & Clinical Immunology 6:5, pages 390-398.
Crossref
Crossref
Mario Cazzola & Maria Gabriella Matera. (2006) The effective treatment of COPD: Anticholinergics and what else?. Drug Discovery Today: Therapeutic Strategies 3:3, pages 277-286.
Crossref
Crossref
Paul A. Glossop & David A. Price. 2006. Annual Reports in Medicinal Chemistry Volume 41. Annual Reports in Medicinal Chemistry Volume 41
237
248
.
Robin A. Fairhurst, Diana Janus & Annabel Lawrence. (2005)
Synthesis of the Marine Sponge Derived β
2
-Adrenoceptor Agonist S1319
. Organic Letters 7:21, pages 4697-4700.
Crossref
Crossref